Cellyan Biotechnology Co., Ltd HKPD
Other Pharmaceuticals · IPO 2025 · data as of November 13, 2026
Cellyan Biotechnology Co., Ltd (HKPD) is a healthcare company listed in the US with a market value of about $4M. In fiscal year 2026 it had revenue of $13M and net income of -$1M, a net margin of -8.5%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -119%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 81% below the current price.
About Cellyan Biotechnology Co.
Cellyan Biotechnology Co. is listed in the US and classified in other pharmaceuticals, IPO year 2025. Revenue went from $13M in 2023 to $13M in 2026, growth of about 2.3% a year. It was profitable in 2 of the last 4 years in our data. Its share count fell by 67% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $13M | $20M | $17M | $13M |
| Net income | -$1M | -$27056 | $1M | $998196 |
| Free cash flow | -$794145 | $499298 | -$447066 | $2M |
| EPS (diluted) | $-0.46 | $-0.00 | $0.18 | $0.13 |
| Net margin | -8.5% | -0.1% | 8.0% | 8.0% |
| ROIC | — | -26.3% | -30.7% | -299.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Cellyan Biotechnology Co. stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 81% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cellyan Biotechnology Co. pay a dividend?
Not currently.
Is Cellyan Biotechnology Co. a good stock to buy?
We do not give buy or sell advice. Cellyan Biotechnology Co. scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.